The FDA has asked Swiss drugmaker Novartis AG to conduct more clinical tests on Galvus, its treatment for diabetes. The drug, already approved in Europe and other markets, was expected to be launched in the U.S. last year. Novartis is still in talks with the FDA, but may stop seeking agency approval if the requirements become too burdensome, chief executive David Vasella said.

Related Summaries